![]() Price Information Vendor Info More Products. The average trading volume of BPMC on Augwas 728.85K shares. BPMC, Fenobucarb, is a most popular pesticide for plant hopper in worldwide. BPMC is a low mammalian toxic carbamate with a good action against leafhoppers and. The public float for BPMC is 59.83M, and at present, short sellers hold a 6.35 of that float. ![]() Get the latest Zacks research report on BPMC - FREE. The average price estimated by analysts for BPMC is 73.94, which is 24.54 above than the current price. The beta is 0.74, so BPMCs price volatility has been lower than the market average. Brand: MAXWIN Technical Name: Fenobucarb (BPMC) 50 EC Packaging Type. Stock Price Statistics The stock price has decreased by -31.14 in the last 52 weeks. This article used data provided by Zacks Investment Research via . Hindustan Agro - Offering BPMC Fenobucarb 50 EC Insecticide, Bottle, 100 Ml at Rs 480/piece in Bijnor, Uttar Pradesh. Blueprint Medicines Corporation BPMC reported a loss of 2.23 per share for third-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of 2.51. Packaging Size: 100 ml., 250 ml., 500 ml. The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. And so with BPMC crossing above that average target price of $103.85/share, investors in BPMC have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $103.85 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Blueprint Medicines Corp: ![]() In the first section, we are going to analyze the 30-day SMA of Blueprint Medicines Corporation (BPMC) share price for recent 52 weeks between -11. 1 Blueprint Medicines Corporation (BPMC) Stock Trend Based On 30 Days Moving Average. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.But the whole reason to look at the average BPMC price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. That report just uses the close and beginning prices to assess trends. and changed its name to Blueprint Medicines Corporation in June 2011. The average of price targets set by Wall Street analysts indicates a potential upside of 61.4 in Blueprint Medicines (BPMC). Currently, there are 59.88 million shares of Blueprint Medicines Corp stock. During the last market session, Blueprint Medicines Corp’s stock traded between 42.40 and 43.67. Blueprint Medicines Corp is up 5.64 from its previous closing price of 42.57. The company was formerly known as Hoyle Pharmaceuticals, Inc. The average twelve-month price prediction for Blueprint Medicines is 76.20 with a high price target of 114.00 and a low price target of 38.00. As of March 29, 2023, 4:00 PM CST, Blueprint Medicines Corp’s stock price was 44.97. Proteovant Therapeutics CStone Pharmaceuticals Genentech, Inc. Blueprint Medicines 's market cap is calculated by multiplying BPMC's current stock price of 49.30 by BPMC's total outstanding shares of 60,664,749. ![]() It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive BLU- 222 to treat patients with cyclin E aberrant cancers and BLU-852 for the treatment of advanced cancers. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC) and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. Track Blueprint Medicines Corp (BPMC) Stock Price, Quote, latest community messages, chart, news and other stock related information. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders and Fisogatinib. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |